<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388010</url>
  </required_header>
  <id_info>
    <org_study_id>NU325</org_study_id>
    <nct_id>NCT01388010</nct_id>
  </id_info>
  <brief_title>Study of the Effect of a Fermented Dairy Product on Gastrointestinal Well Being in Adult Women</brief_title>
  <official_title>&quot;Effect of the Consumption of a Fermented Dairy Product on Gastrointestinal Well-being in a Healthy Population of Women With Minor Digestive Symptoms&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a commercially available fermented
      dairy product containing probiotics (4 weeks, twice a day) on the improvement of
      gastrointestinal well being and digestive symptoms in adult women reporting minor digestive
      troubles among the general population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">336</enrollment>
  <condition>Healthy Adult Women</condition>
  <arm_group>
    <arm_group_label>1 = Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 - Intervention 1 (probiotics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 = Control product</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 2 - Intervention 2 (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1-Fermented Probiotic Dairy Product (test)</intervention_name>
    <arm_group_label>1 = Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2-Milk-based non-fermented dairy product(control)</intervention_name>
    <arm_group_label>2 = Control product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female free-living subject aged from 18 to 60 years.

          -  Subject with a body mass index between 18 and 30.

          -  Subject with minor digestive symptoms as defined by screening questionnaire of
             frequency of digestive symptoms.

          -  Subject with normal stool frequency

        Exclusion Criteria:

          -  Subject with a diagnosis of Irritable Bowel Syndrome (IBS) or other functional bowel
             disease (constipation, diarrhoeaâ€¦)

          -  Subject with known organic disease, including an inflammatory bowel disease, a benign
             or malign tumour of intestine or colon and significant systemic disease

          -  Subject under prescription for medication for digestive symptoms such as
             anti-spasmodic, laxatives and anti-diarrheic drugs

          -  Subject having taken antibiotics in the last 4 weeks

          -  Pregnant subject or subject planning to become pregnant during the study;
             breast-feeding subject.

          -  Subject with known lactose intolerance or immunodeficiency

          -  Subject with known allergy to product component (milk protein for example)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RPS Research France</name>
      <address>
        <city>Caen</city>
        <zip>14052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>July 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>gastrointestinal well being</keyword>
  <keyword>digestive symptoms</keyword>
  <keyword>healthy population</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
